Novel scientific insights to unlock the full potential of B cell therapeutics for cancer treatment opportunities using immunotherapy and B cell-driven rare diseases

Akamara Theraputics: Reimagining Immunotherapy for Cancer & Rare Disease

  • Novel scientific insights to unlock the full potential of B cell therapeutics
  • Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
  • Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
  • Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
  • Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
  • Financing underway to fund AT-1965 clinical initiation and development

What You Will Learn From This Webinar

  • The importance of B Cells role in cancer immunotherapy
  • Why AT-1965 is Poised to Lead the Next Frontier in Cancer Immunotherapy
  • How our Phase 1 Study Design Provides a Strong Opportunity to Detect Clinical Activity in Cancer Patients
  • How Reimagining Immunotherapy Will Move B Cell Treatments Beyond the Limits of History